Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ167MR)

This product GTTS-WQ167MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ167MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5328MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ4296MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ5176MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ15379MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ8887MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ7626MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ13356MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ4759MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BPS-804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW